1. ¹Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
2. ²Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrücken, Germany

Correspondence: K Piotrowska, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrae 112, D-70376 Stuttgart, Germany. E-mail: kamilla.piotrowska@ikp-stuttgart.de

^*These authors contributed equally to this work.

Received 18 July 2005; Revised 4 August 2005; Accepted 8 August 2005; Published online 19 September 2005.

Abstract

Telomerase inhibition represents a promising approach to anticancer treatment. In order to clarify the therapeutic potential of telomerase inhibitors we examined different substances (small molecule compounds BIBR1532 and BRACO19, as well as hTR antisense oligonucleotides 2'-O-methyl RNA and PNA) in A-549, MCF-7, and Calu-3 cell lines in a cell-free TRAP assay. We demonstrated that each of the tested agents inhibited telomerase in all used cell lines and that the antisense oligonucleotides represent the most potent inhibitors. Interestingly, upon evaluating the specificity of telomerase inhibitors we found out that not all agents acted specifically against telomerase. We observed that BRACO19 and PNA had an inhibitory effect also on PCR amplification of the TSR8 oligonucleotide which is provided in the TRAP_EZE^® kit as a PCR control. By modifying the experimental protocol and using a different reverse primer we were able to enhance PNA selectivity, although the PCR inhibition of the TSR8 control template by BRACO19 could not be prevented. We propose an explanation for the lack of target specificity and suggest caution when testing putative telomerase inhibitors, as it appears that some of those substances may not affect specifically telomerase or telomeric G-rich sequences and thus can lead to the misinterpretation of experimental results.